These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3219 related articles for article (PubMed ID: 7337195)

  • 21. Antigens and antibodies in malignant melanoma.
    Merimsky O; Shoenfeld Y; Chaitchik S; Yecheskel G; Fishman P
    Tumour Biol; 1994; 15(4):188-202. PubMed ID: 7939169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Karyometrical and cytochemical studies of Harding-Passey melanoma and Horning-Mitchely kidney tumor. II. Cytochemistry of nucleic acids and proteins.
    el-Faky SM; Fahmy TY; Abdo SE
    Acta Histochem; 1971; 41(1):92-101. PubMed ID: 5004563
    [No Abstract]   [Full Text] [Related]  

  • 23. Lymphocyte-melanoma interaction: role of surface molecules.
    Becker JC; Bröcker EB
    Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon.
    Ziai MR; Imberti L; Tongson A; Ferrone S
    Cancer Res; 1985 Nov; 45(11 Pt 2):5877-82. PubMed ID: 3931909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations of membrane glycoproteins in malignant cells.
    Warren L; Buck CA; Tuszynski GP
    Dev Biol Stand; 1979; 42():177-82. PubMed ID: 223919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD109 expression levels in malignant melanoma.
    Ohshima Y; Yajima I; Kumasaka MY; Yanagishita T; Watanabe D; Takahashi M; Inoue Y; Ihn H; Matsumoto Y; Kato M
    J Dermatol Sci; 2010 Feb; 57(2):140-2. PubMed ID: 20034764
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of hybridoma-exchange antibodies.
    Lloyd KO; Albino A; Houghton A
    Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
    [No Abstract]   [Full Text] [Related]  

  • 28. Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications.
    Esclamado RM; Gown AM; Vogel AM
    Am J Surg; 1986 Oct; 152(4):376-85. PubMed ID: 3766867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of melanoma-associated antigens using fixed tissue screening of antibodies.
    Atkinson B; Ernst CS; Ghrist BF; Herlyn M; Blaszczyk M; Ross AH; Herlyn D; Steplewski Z; Koprowski H
    Cancer Res; 1984 Jun; 44(6):2577-81. PubMed ID: 6722794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells.
    Pietra G; Mortarini R; Parmiani G; Anichini A
    Cancer Res; 2001 Nov; 61(22):8218-26. PubMed ID: 11719453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein patterns of benign and malignant human melanocytes show consistent changes in gene expression.
    Eberle J; Garbe C; Kroumpouzos G; Orfanos CE
    Recent Results Cancer Res; 1995; 139():123-35. PubMed ID: 7597285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactoperoxidase-catalysed iodination of surface proteins on human melanoma cells.
    Roberts GP
    Br J Cancer; 1978 Jul; 38(1):114-21. PubMed ID: 687508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic aspects of melanoma.
    Carey TE
    Crit Rev Clin Lab Sci; 1982; 18(2):141-82. PubMed ID: 6295700
    [No Abstract]   [Full Text] [Related]  

  • 34. S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: a totally dedifferentiated malignant melanoma?
    Laskin WB; Knittel DR; Frame JN
    Am J Clin Pathol; 1995 Jun; 103(6):772-3. PubMed ID: 7785665
    [No Abstract]   [Full Text] [Related]  

  • 35. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
    Holzmann B; Johnson JP; Kaudewitz P; Riethmüller G
    J Exp Med; 1985 Feb; 161(2):366-77. PubMed ID: 3973533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface proteins on Cloudman melanoma cells.
    Nordlund JJ; Cone RE; Ackles A; Gershon R
    Cell Immunol; 1980 Dec; 56(2):273-85. PubMed ID: 7471218
    [No Abstract]   [Full Text] [Related]  

  • 37. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype.
    Breza TS; Magro CM
    J Cutan Pathol; 2005 Nov; 32(10):685-9. PubMed ID: 16293181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes.
    Bordoni R; Fine R; Murray D; Richmond A
    J Cell Biochem; 1990 Dec; 44(4):207-19. PubMed ID: 2095366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth control of melanoma cells and melanocytes by cytokines.
    Krasagakis K; Garbe C; Zouboulis CC; Orfanos CE
    Recent Results Cancer Res; 1995; 139():169-82. PubMed ID: 7597288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer.
    Vijayasaradhi S; Houghton AN
    Adv Pharmacol; 1995; 32():343-74. PubMed ID: 7748799
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 161.